Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;24(4):435-448.
doi: 10.2174/1566524023666230417112543.

Emerging Treatment Approaches for COVID-19 Infection: A Critical Review

Affiliations
Review

Emerging Treatment Approaches for COVID-19 Infection: A Critical Review

Alok Bharadwaj et al. Curr Mol Med. 2024.

Abstract

In the present scenario, the SARS-CoV-2 virus has imposed enormous damage on human survival and the global financial system. It has been estimated that around 111 million people all around the world have been infected, and about 2.47 million people died due to this pandemic. The major symptoms were sneezing, coughing, cold, difficulty breathing, pneumonia, and multi-organ failure associated 1with SARS-CoV-2. Currently, two key problems, namely insufficient attempts to develop drugs against SARSCoV-2 and the lack of any biological regulating process, are mostly responsible for the havoc caused by this virus. Henceforth, developing a few novel drugs is urgently required to cure this pandemic. It has been noticed that the pathogenesis of COVID-19 is caused by two main events: infection and immune deficiency, that occur during the pathological process. Antiviral medication can treat both the virus and the host cells. Therefore, in the present review, the major approaches for the treatment have been divided into "target virus" and "target host" groups. These two mechanisms primarily rely on drug repositioning, novel approaches, and possible targets. Initially, we discussed the traditional drugs per the physicians' recommendations. Moreover, such therapeutics have no potential to fight against COVID-19. After that, detailed investigation and analysis were conducted to find some novel vaccines and monoclonal antibodies and conduct a few clinical trials to check their effectiveness against SARSCoV- 2 and mutant strains. Additionally, this study presents the most successful methods for its treatment, including combinatorial therapy. Nanotechnology was studied to build efficient nanocarriers to overcome the traditional constraints of antiviral and biological therapies.

Keywords: Peptide repurposing; SARS-CoV-2; antiviral medications.; proteomics; therapeutics; transcriptomics.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Puelles V.G.; Lütgehetmann M.; Lindenmeyer M.T.; Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 2020,383(6),590-592 - DOI - PubMed
    1. Coperchini F.; Chiovato L.; Croce L.; Magri F.; Rotondi M.; The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020,53,25-32 - DOI - PubMed
    1. Sette A.; Crotty S.; Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021,184(4),861-880 - DOI - PubMed
    1. Iacob S.; Iacob D.G.; SARS-coV-2 treatment approaches: Numerous options, no certainty for a versatile virus. Front Pharmacol 2020,11,1224 - DOI - PubMed
    1. Hillen H.S.; Structure and function of SARS-CoV-2 polymerase. Curr Opin Virol 2021,48,82-90 - DOI - PubMed